Resources from the same session
LBA31 - Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)
Presenter: Kathleen Moore
Session: Proffered Paper - Gynaecological cancers 2
Resources:
Abstract
Slides
Webcast
805O - ICON8: Overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment
Presenter: Andrew Clamp
Session: Proffered Paper - Gynaecological cancers 2
Resources:
Abstract
Slides
Webcast
LBA32 - Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study
Presenter: Robert Coleman
Session: Proffered Paper - Gynaecological cancers 2
Resources:
Abstract
Slides
Webcast
807O - Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant (advanced or recurrent) ovarian cancer: Open-label, randomized trial in Japan (NINJA trial)
Presenter: Kohei Omatsu
Session: Proffered Paper - Gynaecological cancers 2
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA31 and 805O
Presenter: Isabelle Ray-Coquard
Session: Proffered Paper - Gynaecological cancers 2
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Isabelle Ray-Coquard
Session: Proffered Paper - Gynaecological cancers 2
Resources:
Webcast
Invited Discussant LBA32 and 807O
Presenter: Ana Oaknin
Session: Proffered Paper - Gynaecological cancers 2
Resources:
Slides
Webcast